Ngs Tools was Twist Bioscience’s largest product and service line in fiscal 2025, bringing in $208.10M of $376.57M (55%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ngs Tools | $99.31M | $123.71M | $169.13M | $208.10M | |||||
| Synthetic Genes | $61.51M | $73.54M | $92.68M | $113.60M | |||||
| Antibody Discovery | $24.17M | $23.17M | $20.33M | $23.45M | |||||
| Oligo Pools | $12.42M | $14.49M | $16.91M | $20.23M | |||||
| Dna Libraries | $6.15M | $10.20M | $13.93M | $11.18M | |||||
| Dna & Biopharma Libraries | — | — | — | — | |||||
| Total | $203.57M | $245.11M | $312.97M | $376.57M |
Twist Bioscience brought in $376.57M from its five product and service lines in fiscal 2025, the year ended September 30, 2025. That was up 20.3% from $312.97M in fiscal 2024. Ngs Tools was the largest at $208.10M (55.3%), ahead of Synthetic Genes at $113.60M (30.2%) and Antibody Discovery at $23.45M (6.2%). The other two lines brought in $31.41M combined.
Compared with fiscal 2024, Ngs Tools grew fastest, up 23.0% to $208.10M, while Dna Libraries fell the most, down 19.7% to $11.18M. From fiscal 2022 to 2025, combined revenue from these lines grew from $203.57M to $376.57M, a compound annual growth rate of 22.8%. Ngs Tools' share of the total rose from 48.8% to 55.3%.
Americas was Twist Bioscience’s largest region in fiscal 2025, bringing in $225.58M of $376.57M (60%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Americas | $122.47M | $151.26M | $193.88M | $225.58M | |||||
| Emea | $62.08M | $71.39M | $92.57M | $124.24M | |||||
| United States | — | — | — | — | |||||
| Apac | $19.01M | $22.46M | $26.52M | $26.75M | |||||
| Asia Pacific | — | — | — | — | |||||
| North America | — | — | — | — | |||||
| Total | $203.57M | $245.11M | $312.97M | $376.57M |
Twist Bioscience brought in $376.57M from its three regions in fiscal 2025, the year ended September 30, 2025. That was up 20.3% from $312.97M in fiscal 2024. Americas was the largest at $225.58M (59.9%), ahead of Emea at $124.24M (33.0%) and Apac at $26.75M (7.1%).
Compared with fiscal 2024, Emea grew fastest, up 34.2% to $124.24M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $203.57M to $376.57M, a compound annual growth rate of 22.8%. Americas' share held steady at about 59.9%.
Healthcare was Twist Bioscience’s largest revenue line in fiscal 2025, bringing in $215.09M of $376.57M (57%).
| Information by industry sector. | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Healthcare | $106.36M | $137.15M | $168.96M | $215.09M | |||
| Industrial Chemicals/Materials | $57.94M | $59.32M | $83.47M | $93.25M | |||
| Academic Research | $37.10M | $45.85M | $58.45M | $65.86M | |||
| Food/Agriculture | $2.17M | $2.79M | $2.09M | $2.37M | |||
| Total | $203.57M | $245.11M | $312.97M | $376.57M |
Twist Bioscience brought in $376.57M from its four revenue lines in fiscal 2025, the year ended September 30, 2025. That was up 20.3% from $312.97M in fiscal 2024. Healthcare was the largest at $215.09M (57.1%), ahead of Industrial Chemicals/Materials at $93.25M (24.8%) and Academic Research at $65.86M (17.5%). The remaining revenue line, Food/Agriculture, brought in $2.37M.
Compared with fiscal 2024, Healthcare grew fastest, up 27.3% to $215.09M. Every revenue line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $203.57M to $376.57M, a compound annual growth rate of 22.8%. Healthcare's share of the total rose from 52.3% to 57.1%.
Twist Bioscience (TWST) reports its revenue by product and service, by geography and by information by industry sector.. In fiscal 2025, Ngs Tools was its largest product and service line, bringing in $208.10M (55.3% of the total), followed by Synthetic Genes at $113.60M (30.2%).
Ngs Tools was Twist Bioscience's largest product and service line in fiscal 2025, bringing in $208.10M, or 55.3% of the $376.57M total across its five product and service lines.
Americas was Twist Bioscience's largest region in fiscal 2025, bringing in $225.58M, or 59.9% of the $376.57M total across its three regions.
Healthcare was Twist Bioscience's largest revenue line in fiscal 2025, bringing in $215.09M, or 57.1% of the $376.57M total across its four revenue lines.
Among Twist Bioscience's product and service lines that make up at least 2% of revenue, Ngs Tools grew fastest in fiscal 2025, up 23.0% from $169.13M to $208.10M.
Every figure comes from Twist Bioscience's annual financial filings, as reported. Each line keeps the name Twist Bioscience gives it, and years follow its fiscal calendar.
Twist Bioscience's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.